Company ProfilePremium

Axtel Industries Limited

Company Profile Analysis

Ticker: 523850.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Axtel Industries Limited - Company showcase

Year Founded & Workforce

1991

228 Employees

Axtel Industries Limited logo

Axtel Industries Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Axtel Industries Limited Overview

Note on the NSE listing. Several platforms (Screener.in, Upstox, Sharpely, Anand Rathi) display an NSE symbol "AXTEL" and NSE prices. Others (Nirmal Bang, BFSL/Vogue) state the company is not traded on NSE. No dated NSE listing announcement was retrieved, so the BSE listing is the only one confirmed in this research.

Axtel Industries is a niche Indian original equipment manufacturer (OEM) of engineered process systems for the food-processing value chain. It designs, fabricates, automates and commissions both turnkey plants and standalone equipment, covering raw-material reception, bulk-solids handling, size reduction, sieving, mixing, steam sterilisation, chocolate moulding and final processing. Its customers are large FMCG, confectionery, spice, dairy, bakery, beverage, malted-drink and aqua-feed processors, plus a smaller base in pharmaceuticals and chemicals. The company runs a single 40,000 m² campus at Halol, near Vadodara, and has long-standing technical associations with Wenger (USA) for extrusion and AnuTec (Switzerland) for powder handling. It is a Gold-certified OEM partner of Rockwell Automation. Financially, Axtel is small (FY2026 revenue ₹223.8 crore), debt-free, cash-generative and a high dividend payer. Its fortunes are tied to the food industry's capex cycle and to the mix of complex orders in a given year. A 2026 exclusive licence for IISc cryogenic grinding technology signals a move into non-food ultra-fine powders.


Company's own description

The company's MD&A (as reproduced by IIFL) describes Axtel as engaged in manufacturing custom-designed food-processing plants and machinery to each client's requirements and specifications. It calls itself a leading supplier of process engineering equipment and turnkey systems to the food and pharmaceutical industries. The MD&A states that the company operates in only one segment: manufacturing food-processing equipment. It links the company's growth directly to growth in the food-processing industry. [Source: Axtel MD&A via IIFL; Screener.in "About", citing Annual Report 2024]

The corporate website says Axtel brings more than 33 years of experience in customised solutions for food processing. It cites expertise in turnkey systems, product development and customer service, and a corporate policy it calls the "4C approach": Comprehensive Process Knowledge, Continuous Product Innovation, Commitment to Quality and Customer-Centric Approach. [Source: axtelindia.com/our-company]

Business model

Axtel is a project-based, engineer-to-order (ETO) capital-goods business. The value chain runs as follows:

  1. Process engineering and design. In-house designers conceptualise process flows, size equipment and develop 3D plant layouts using CAD.

  2. Fabrication. Stainless-steel fabrication uses laser cutting, water-jet cutting, inverter TIG welding, CNC forming, grit blasting, painting and polishing. Heat treatment and precision machining are outsourced to strategic partners.

  3. Electrical and automation. Panels are designed to IEC standards. PLC, HMI and SCADA software is developed in-house, and efficiency is monitored to ISA-88/95 standards.

  4. Installation and commissioning, followed by after-sales service.

[Source: axtelindia.com]

According to CARE, raw materials are procured mainly when an order is received, which limits but does not remove exposure to commodity prices. Contracts are mostly fixed-price. [Source: CARE Ratings PR, 5 Feb 2026]

Revenue model mix

Revenue typeCharacterDisclosure status
Turnkey process systems (complete plants)High-value, multi-month, milestone-billed projectsRevenue split not publicly disclosed
Individual process equipmentStandard or customised machines supplied singly—
Spares, service and commissioningRecurring aftermarket—
Licensing / royaltyNone at present; the IISc licence (Sept 2026) makes Axtel a royalty payer, not a recipientNot applicable
Subscription—Not applicable

Our independent characterisation is that revenue is overwhelmingly product and project revenue recognised as orders are executed and dispatched. Aftermarket revenue is probably a minority share, but its size is not disclosed.

Customer types and end-markets

CARE describes a base of more than 150 reputed customers, mainly large organised FMCG companies in India and abroad. The top-customer list changes each year with order flow, apart from a few marquee accounts. [CARE, Feb 2026]

End-markets disclosed by the company (via Capital Market/Business Standard and CARE):

  • confectionery and chocolate

  • malted drinks

  • aqua feed

  • ready-to-eat foods

  • bakery and biscuits

  • dairy products

  • beverages

  • instant mixes

  • snack foods

  • spices, condiments and seasonings

Secondary markets are pharmaceuticals, chemicals and cosmetics (grinding and milling). [StockAnalysis company profile; IIFL summary]

Independent characterisation

Axtel is best understood as a specialist bulk-solids and food-process engineering house. Its moat is application know-how (especially spice sterilisation, powder handling and chocolate lines), hygienic design (it is a registered EHEDG member), and in-house automation. It is not a high-volume machinery maker. The economics follow from that:

Lumpy revenue: FY2025 revenue fell 20% and FY2026 rose 25%.

Mix-driven margins: EBITDA margin swung between 12% and 20% in FY2022–FY2026.

Low capital intensity: Capex was ₹2–11 crore a year.

Strong customer advances: Payable and advance days are high, which helped the cash conversion cycle fall to 76 days in FY2026.

Strategy

Stated strategy themes

  • Customer-centric, engineer-to-order solutions, i.e. the 4C approach and "Right – the first time" delivery.

  • Full value-chain coverage, from raw-ingredient handling to final processing.

  • Continuous product innovation, including an R&D and test centre for size reduction, mixing, sieving and conveying.

Hygienic design and automation leadership: through EHEDG membership and Rockwell Gold OEM partnership.

  • Import substitution / Atmanirbhar Bharat, explicitly invoked in the IISc licence announcement.

Strategic initiatives (last 24 months)

InitiativeDateDescriptionTarget / KPI
ESOP 2024Introduced 2024 (implemented FY2025–26)Employee stock options to attract and retain key talent—
Capacity expansion (consolidation)Opened Nov 2023; ramp-up FY2024–FY2026New sheds, material handling, solar panels, health centreSupports CARE's ₹350 crore TOI upgrade trigger
Automation upgrade (Rockwell Automation)Case study published c. 2024–25Fully automated chocolate moulding lines; spice-blending reporting covering 100+ ingredientsPrecision, compliance, safety
R&D and test centreOngoing (website)Trial facility for bulk-solids processesNot quantified
IISc cryogenic grinding licence7 Sep 2026Exclusive commercialisation of a counter-rotating pin mill plus cryogenic conveying system; prototype transferredConsideration up to ₹3 crore plus sales-linked royalties capped at ₹3 crore
Higher shareholder payoutsFY2025–FY2026Payout of 99% in FY2025 and 62% in FY2026No formal policy target retrieved
Solar energyNov 2023Rooftop solar at the expanded plantCapacity not disclosed

Cost programmes

None formally announced. Cost discipline appears mainly through procuring materials only when orders are received (CARE).

Medium-term targets and guidance

Management does not publish numerical guidance, investor presentations or earnings-call transcripts (none were retrieved). The only quantified external benchmarks are CARE's rating sensitivities:

Upside triggers: total operating income above ₹350 crore with PBILDT margin above 16%; tangible net worth above ₹200 crore; operating cycle below 90 days.

Downside triggers: total operating income below ₹200 crore on a sustained basis; gearing above 0.5x; operating cycle above 150 days.

Products & Services

Because Axtel has a single segment, the catalog is organised by the company's own two product families: Process Systems (turnkey lines) and Process Equipment (individual machines). Launch years, versions and prices are not publicly disclosed for any product. Pricing is project-specific and quoted, mostly on fixed-price contracts (CARE).

Process Systems (turnkey)

Product lineWhat it doesTypical target customerNotes
Solutions for Chocolates & ConfectioneryComplete chocolate lines, from chocolate paste mixers to moulding lines and cooling tunnels; includes depositors, temperers and thermoregulation unitsChocolate and confectionery majorsMoulding lines fully automated with Rockwell Automation controls (Rockwell case study)
Ingredients Management SystemsAutomated reception, storage, dosing and weighing of major, minor and micro ingredients; the Rockwell case study cites management of 100+ ingredients in spice processingFMCG, bakery, malted drinks, instant mixes, seasoningIntegrated PLC/SCADA batch control to ISA-88
Size Reduction SystemsComplete grinding and milling plants for foodstuffs, pharma, cosmetics and chemicalsSpice, sugar, pharma, chemical processorsA cryogenic option is being added via the IISc licence (2026)
Sieving SystemsPlant-level sieving and grading lines for powders and granulesFlour, sugar, milk powder, pharmaCore offering
Mixing SystemsBatch and continuous blending systems, including cryogenic mixersInstant mixes, seasoning, nutritionCore offering
Spices Processing SystemsCleaning, grinding, pasteurisation and steam sterilisation of whole and ground spicesSpice brands and exportersA flagship niche; serves export food-safety requirements
Steam Sterilization SystemsMicrobial load reduction for spices, herbs and seeds using steamSpice exporters, seasoning makersFlagship niche offering
Customized Processing SolutionsBespoke lines, e.g. food and feed extrusion (with Wenger technology), conveyor dryers and dehydration systems, frying systems, dewateringAqua feed, pet food, snacks, RTEExtrusion is linked to the Wenger association

[Source: axtelindia.com menu; IIFL summary; Tradomate; Rockwell case study]

Process Equipment (individual machines)

Equipment familyNamed products
Solids handlingSack tip stations, bulk loaders, belt conveyors, cyclones, reverse jet filters, screw feeders with valve, metering screw feeders, magnets, dual tunnel diverter valves, blowers, idler roller conveyors, Z-bucket elevators, dump booths, octabin and tote tilters
Storage and dischargeBag handling systems, storage tanks, intermediate bulk containers (IBCs), rotary vane valves, table feeders, bin activators, pneumatic knife gate and butterfly valves, cone discharge units, bagging stations, liquid injection pressure tanks, storage bins
Size reductionHammer mills, universal mills, nibblers, lump breakers, cone mills, knife mills, shredders, roller mills
Sieving and straining / cleaning and gradingRotary sifters, gyratory sifters, inline rotary and gyratory sifters, graders, screeners, destoners, zig-zag classifiers, chocolate vibro-sieves, vacuum gravity separators
Mixing and blendingMixers, process tanks, dough kneaders, cryogenic mixers (model names not disclosed)
Specialised process equipmentSteam sterilisers, moulding-line cooling tunnels, curved and dryer conveyors, chocolate depositors, temperers, thermoregulation units, extruders, khoa-making machines, dewatering screw presses, vacuum cabinet dryers, band dryers, scraped-surface heat exchangers, IBC/big-bag filling machines, horizontal wiped-film evaporators, shell-and-tube heat exchangers, steaming tunnels

[Source: StockAnalysis company description, compiled from company materials; axtelindia.com]

Services

Engineering services: process-flow design, equipment sizing and 3D plant layouts.

Electrical and automation: IEC-compliant panel design and manufacture in a dust-proof assembly area, and PLC/HMI/SCADA programming.

Installation, commissioning and after-sales: - Product development and trials: an R&D and test centre for size reduction, mixing, sieving and pneumatic/mechanical conveying is described as "in the process of being established".

Flagship and emerging offerings

Flagship: spice steam sterilisation, chocolate moulding lines, ingredient-management automation, and powder-handling systems (with AnuTec know-how).

Emerging (2026): a high-performance grinding system with a counter-rotating pin mill and cryogenic conveying, licensed exclusively from FSID-IISc. It targets ultra-fine powders of polymers, rubbers, resins and natural materials, which are currently import-dependent. [BSE Reg. 30, 7 Sep 2026]

Financial Narrative

Basis: standalone, Ind AS, ₹ crore. Primary aggregation is Screener.in (BSE filings); revenue and gross profit are from StockAnalysis. FY2022–FY2026 = years ended 31 March 2022–2026.

Income statement

Notes:

  • Gross profit is aggregator-derived (StockAnalysis: total revenue less cost of revenue) and is not a company-reported line.

  • EBIT is derived as EBITDA less depreciation.

  • Diluted EPS equals basic EPS in reported figures; ESOP 2024 dilution was immaterial or not reported.

  • Net profit for FY2022–FY2023 is derived from EPS × 1.615 crore shares. FY2024–FY2026 are company-reported (₹32.13 crore, ₹18.03 crore, ₹31.16 crore).

  • DPS is per fiscal year of declaration:

    • FY2022: final ₹2.

    • FY2023: final ₹3.

    • FY2024: interim ₹6.

    • FY2025: interim ₹5 plus final ₹6.

    • FY2026: interim ₹12. The Board on 7 May 2026 recommended treating it as the final dividend, and the 62% payout on EPS of ₹19.29 is consistent with ₹12 in total.

Revenue CAGR FY2022–FY2026 (derived): (223.8/144.0)^(1/4) − 1 = 11.7%. Screener.in's trailing 5-year sales CAGR is 8% and 10-year is 13%. Its 5-year profit CAGR is 4%; 3-year is 15%.

Commentary. Revenue follows the food industry's capex cycle and order execution, not a steady growth path.

FY2022: revenue fell 5.7%, and EBITDA margin compressed to 12% as steel inflation hit fixed-price contracts.

FY2023–FY2024: two years of about 24–25% growth took revenue to a record ₹223 crore. EBITDA margin expanded to about 20% thanks to operating leverage and a richer mix of complex orders.

FY2025: a step back. CARE attributes the 20% revenue decline and the 615 bps PBILDT margin contraction (to 13.92%) to slower end-user capex, operating deleverage and lower execution of high-margin complex orders.

FY2026: a sharp V-shaped recovery to ₹223.8 crore (+25.3%) with PAT up 72.8%. The improvement was back-ended: Q2–Q4 delivered 87% of annual revenue.

Gross margin: reached a 5-year high of about 58% in FY2026 (aggregator basis). This suggests better pricing or mix, but "other operating expenses" (which likely include subcontracting) also rose sharply, so EBITDA margin (18%) did not fully match the gross-margin gain.

Quarterly trajectory (last 13 quarters)

[Source: Screener.in quarterly results, from BSE filings]

Quarterly commentary.

Q1 is seasonally weak: Q1 FY2026 revenue was ₹27.2 crore (−39% YoY) and Q1 FY2027 was ₹32.3 crore (+18.7% YoY). Q1 FY2027 PAT rose only 3.2% to ₹1.96 crore, and OPM of 7.8% was the second-lowest in 13 quarters. The stock fell about 8% on the day of the results (6 Aug 2026).

Q4 FY2025 tax: The effective tax rate was −6% (a tax credit), which flattered that quarter's PAT.

TTM to June 2026 (derived): revenue ₹228.9 crore, PAT ₹31.2 crore, EPS ₹19.32.

Balance sheet

Notes:

  • Total assets are company-reported at ₹215.64 crore for FY2026 (FilingReader).

  • Goodwill and intangibles are not separately disclosed and appear immaterial.

  • Working capital is not disclosed as a line item. Screener's "working capital days" fell from 105 (FY2022) to −7 (FY2026).

  • Book value per share for FY2022–FY2025 is derived (net worth / 1.615 crore shares).

  • CARE reports tangible net worth of ₹134 crore at 30 September 2025, and free liquidity of ₹99 crore at the same date.

  • Screener rounds borrowings to zero for FY2022–FY2026; CARE confirms "no outstanding debt" at 31 March 2025 and 30 September 2025.

Commentary. The balance sheet is pristine.

No debt: Debt was retired after FY2020, when borrowings were ₹8 crore.

Growing treasury: Investments, most likely liquid and mutual-fund holdings, rose from ₹18 crore to ₹81 crore over five years. CARE's ₹99 crore free-liquidity figure (Sept 2025) equals roughly 15% of today's market capitalisation.

Net worth growth was slow in FY2026: It rose only ₹2 crore because dividends paid (about ₹29 crore, derived) nearly matched PAT of ₹31.2 crore. Management is effectively distributing most of its earnings.

Fixed assets doubled: from ₹13 crore (FY2023) to ₹25 crore (FY2024) with the November 2023 expansion.

Cash flow

Notes:

  • Capex is derived as CFO minus FCF.

  • Dividends paid are derived from the per-share cash dividends paid within each fiscal year × 1.615 crore shares:

    • FY2022: FY2021 final ₹3.

    • FY2023: FY2022 final ₹2.

    • FY2024: FY2023 final ₹3 plus FY2024 interim ₹6.

    • FY2025: FY2025 interim ₹5.

    • FY2026: FY2025 final ₹6 plus FY2026 interim ₹12.

  • CARE reports CFO of ₹38 crore for FY2024 and ₹31 crore for FY2025, consistent with Screener.

Commentary.

FY2022: was the only negative-CFO year (−₹11 crore). Receivables rose to 116 days and inventory to 175 days as large orders sat mid-execution.

FY2026: was exceptional: CFO of ₹71 crore was about 2x EBITDA, driven by higher customer advances and payables (payable days rose from 101 to 125) and lower inventory days (155 to 128). Some of this release may reverse if order intake slows.

  • Cumulative FY2022–FY2026 FCF of about ₹127 crore funded about ₹60 crore of dividends and an increase of about ₹63 crore in investments.

Key ratios

Notes:

  • ROE, ROA and asset turnover are derived from Screener P&L and balance sheet data.

  • ROCE is Screener-reported. ROIC is not disclosed; ROCE is the closest proxy, and with no debt and cash excluded, ROIC would be higher.

  • The current ratio and TOL/TNW are from CARE. CARE reports the current ratio as "2.38x as on 31 March 2024 (PY: 1.91x)", so 1.91 is FY2023.

  • Interest coverage for FY2024–FY2025 is from CARE. FY2026 is derived (quarterly EBITDA ₹40.7 crore / interest ₹0.25 crore).

  • Net debt/EBITDA for FY2024–FY2025 is derived from CARE free liquidity and Screener EBITDA.

  • Working-capital days and CCC are from Screener. CARE's "operating cycle" is 121 days for FY2024 and 127 days for FY2025, slightly different because of a different method.

Commentary. Returns are high for an Indian capital-goods company of this size: 5-year average ROE is about 20% and peak ROCE was 41% in FY2024. They are, however, volatile. The most important structural improvement is the cash conversion cycle, which fell from 147 days (FY2024) to 76 days (FY2026). CARE's positive rating trigger is an operating cycle below 90 days; Screener's CCC measure is now below that threshold, though CARE's own methodology may differ.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment revenue from operations (INR Cr)

223.3178.6223.8

Segment YoY revenue growth (%)

24.0-20.025.3

Segment operating profit / EBITDA (INR Cr)

44.123.840.7

Segment EBITDA margin (%)

19.713.318.2

Segment pre-tax profit (INR Cr)

42.923.941.4

Contribution to total revenue (%)

100100100

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

144.0180.1223.3178.6223.8

Revenue growth YoY (%)

-5.725.124.0-20.025.3

Gross profit (INR Cr)

68.784.8116.090.5129.1

Gross margin (%)

47.747.151.950.757.7

Operating profit / EBITDA (INR Cr)

1723442441

EBITDA margin (%)

1213201318

Other income (INR Cr)

54356

Interest expense (INR Cr)

01210

Depreciation (INR Cr)

32345

Operating income EBIT (INR Cr)

1421412036

Operating (EBIT) margin (%)

9.711.718.411.216.1

Profit before tax (INR Cr)

1923432441

Effective tax rate (%)

2625252525

Net profit (INR Cr)

13.817.332.118.031.2

Net margin (%)

9.69.614.410.113.9

EPS basic (INR)

8.5610.7119.8911.1619.29

EPS diluted (INR)

8.5610.7119.8911.1619.29

Dividend per share (INR)

2361112

Dividend payout (%)

2328309962

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1FY24Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Sales (INR Cr)

47.9169.4753.7952.1644.7055.8440.4137.6127.2267.3458.6370.5732.31

Operating profit (INR Cr)

7.0416.6112.687.725.488.884.964.521.5213.1810.8215.172.53

OPM (%)

14.6923.9123.5714.8012.2615.9012.2712.025.5819.5718.4521.507.83

PBT (INR Cr)

7.0116.7512.176.945.349.154.964.492.1713.6210.8214.802.55

Net profit (INR Cr)

5.3211.929.585.314.115.903.264.761.9010.127.9811.161.96

EPS (INR)

3.297.385.933.292.543.652.022.951.186.264.946.911.21

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

131179196189216

Net fixed assets (INR Cr)

1413252831

Capital work in progress (INR Cr)

05010

Investments (INR Cr)

1834355781

Other assets incl. inventory, receivables, cash (INR Cr)

98127135103103

Free liquidity per CARE (INR Cr)

——6079—

Total debt (INR Cr)

00000

Short-term debt (INR Cr)

00000

Long-term debt (INR Cr)

00000

Net debt (INR Cr)

——-60-79—

Equity share capital (INR Cr)

1616161616

Reserves (INR Cr)

658097106108

Total equity / net worth (INR Cr)

8196113122124

Other liabilities incl. customer advances and payables (INR Cr)

5083836691

Book value per share (INR)

50.259.470.075.577.2

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Cash from operating activities (INR Cr)

-1130393171

Capital expenditure (INR Cr)

251178

Free cash flow (INR Cr)

-1325282463

Cash from investing activities (INR Cr)

14-20-9-25-28

Cash from financing activities (INR Cr)

-5-5-16-9-29

Dividends paid, derived (INR Cr)

4.83.214.58.129.1

Share buybacks (INR Cr)

00000

CFO to EBITDA (%)

-3615733156197

Net cash flow (INR Cr)

-2513-314

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

18.219.530.715.325.3

ROA on average assets (%)

11.711.217.19.415.4

ROCE (%)

2226412030

Current ratio (x)

—1.912.38——

Debt to equity (x)

0.000.000.000.000.00

Net debt to EBITDA (x)

——-1.36-3.29—

Interest coverage, PBILDT/interest (x)

——27.8636.80163

Asset turnover (x)

1.211.161.190.931.11

Debtor days

116125816774

Inventory days

175172177155128

Payable days

148153111101125

Cash conversion cycle (days)

14314314712176

Total outside liabilities to tangible net worth (x)

——0.850.58—

Revenue by Region

MetricFY2024FY2025FY2026

Total revenue (INR Cr)

223.3178.6223.8

Capital Markets

Metric1 year3 years5 years10 years

Stock price CAGR (%)

-10-8520

Share Price History

DatePriceSource

19 Sep 2024

460

5paisa

8 Nov 2024

555.65 (market cap ₹898 crore)

Value Research

11 Jul 2025

470 (52-week range then ₹370.5–680)

Kotak

Nov 2025

490

Upstox

2 Apr 2026

389

ICICIdirect

12 Jun 2026

447.95

Torus

6 Aug 2026

465.50 intraday, before closing down about 8% to about ₹432 after results

Value Research; Univest

28 Aug 2026

400.45

Anand Rathi

23 Sep 2026

450.35

StockAnalysis

16 Oct 2026

419

Screener.in

Price series (INR)

Nov 2024

Jul 2025

Axtel share price (INR)

555.65470

Valuation Multiples

MultipleAxtelBasis

Market capitalisation (INR Cr)

677

Screener

P/E (TTM) (x)

21.7

Screener; TTM EPS ₹19.32

P/B (x)

5.4

Derived: ₹419 / BVPS ₹77.2

EV (INR Cr)

about 596

Derived: market cap minus FY2026 investments of ₹81 crore; operating cash not deducted, so EV is overstated

EV/EBITDA TTM (x)

about 14

Derived: ₹596 crore / TTM EBITDA of about ₹41.7 crore

EV/Sales TTM (x)

about 2.6

Derived: ₹596 crore / ₹228.9 crore

Dividend yield (%)

2.87

Screener

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

32361112

Dividend payout ratio (%)

462328309962

Credit Ratings

AgencyFacilityAmount (INR Cr)RatingOutlookDate

CARE Ratings

Fund-based LT/ST: cash credit / packing credit

12.00

CARE A- / CARE A2+

Stable

5 Feb 2026 (reaffirmed)

CARE Ratings

Non-fund-based ST: bank guarantee / letter of credit

37.65

CARE A2+

—

5 Feb 2026

CARE Ratings

Non-fund-based short term

0.35

CARE A2+

—

5 Feb 2026

Moody's / S&P / Fitch

——

Not rated

——

Analyst Conclusions

Management guidance

None published. The only forward indicators are:

  • CARE's citation of an order book of about ₹250 crore at 30 Sep 2025, and its expectation of a "gradual recovery in capex activity of key end-user industries".

Consensus growth expectations

None available; the stock has no sell-side coverage.

Bull case

  1. Cycle upturn plus operating leverage. FY2026 showed that revenue near ₹224 crore delivers about 18% EBITDA margin and about 25% ROE. With an order book of about ₹250 crore and an FMCG capex recovery (Q2–Q4 FY2026 YoY growth of 21–88%), FY2027–28 revenue could reach new highs above the FY2024 peak, with margins near 20%.

  2. Valuation underpinned by cash and yield. About ₹81–99 crore of liquidity (12–15% of market capitalisation), a 2.9% dividend yield and EV/EBITDA of about 14x look undemanding for a debt-free company earning 30% ROCE. Value Research shows Axtel's P/E at a deep discount to peers.

  3. New growth vector. Exclusive IISc cryogenic grinding technology opens non-food markets (polymers, rubbers, resins) with import-substitution tailwinds. The maximum outlay of about ₹6 crore is small relative to ₹31 crore of annual PAT.

Bear case

  1. Structural low growth. The 5-year sales CAGR is only 8% and the profit CAGR 4% (Screener). The company has stayed below about ₹225 crore of revenue for three years, which suggests a ceiling on market reach without new geographies or capacity.

  2. Margin and earnings fragility. Q1 FY2027 OPM of 7.8% and only 3% PAT growth despite 19% sales growth; a 615 bps margin swing in FY2025. Fixed-price contracts and limited pricing power with large buyers (CARE) mean profits can collapse in a downcycle.

  3. Cash flow flattered by working capital, and illiquid governance. FY2026 CFO of ₹71 crore relied on payables stretching to 125 days. Institutional ownership is below 2%, there is no investor communication, and decisions sit with two long-tenured promoters, all of which limit re-rating potential.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Nov 2026Q2 FY2027 results; compare with Q2 FY2026 (sales ₹67.34 crore, PAT ₹10.12 crore) and look for a return of OPM above 18%
Jan–Feb 2027Q3 FY2027 results; annual CARE rating review (watch for movement toward the ₹350 crore TOI and sub-90-day operating-cycle triggers)
1 Mar 2027Start of Ajay Desai's new five-year term
Mar 2027Size of the interim dividend (signal of FY2027 earnings confidence)
May 2027FY2027 audited results; any disclosure of order book or export share
OngoingFirst commercial orders for the cryogenic grinding system; commissioning of the R&D and test centre
OngoingFurther accumulation by Solidarity Advisors or other institutions; any NSE listing clarification
OngoingStainless-steel prices; FMCG capex announcements in India

Analyst verdict

Axtel Industries is a well-run, conservatively financed niche engineering company whose investment case depends almost entirely on the food-processing capex cycle and on how efficiently it converts orders into margin. The evidence over five years is clear. The company earns high returns: ROCE ranged from 20% to 41% between FY2022 and FY2026, with no leverage. It turns those returns into real cash, with about ₹127 crore of free cash flow over five years, and it returns most of that cash to shareholders, paying out 99% in FY2025 and 62% in FY2026. CARE's rating upgrade to A- in 2025 and its reaffirmation in 2026 independently confirm the strength of the balance sheet.

Growth, however, has been unremarkable and highly volatile. Revenue has hit a ceiling of about ₹224 crore twice in three years, and a 20% drop in FY2025 showed how quickly profits fall when complex, high-margin orders slow down. The weak start to FY2027 (Q1 OPM of 7.8%) is consistent with the company's usual seasonality. Even so, it reminds investors that a single strong year does not make a trend.

At about ₹419 per share (21.7x trailing earnings, about 14x EV/EBITDA, 2.9% dividend yield, with roughly 12–15% of market capitalisation in liquid assets), the market is valuing Axtel as a quality cyclical rather than a compounder. That looks fair to modestly undervalued if FY2027 broadly holds FY2026's earnings. The upside case depends on three things: sustained revenue above ₹250 crore backed by the reported order book of about ₹250 crore, commercial traction for the IISc cryogenic grinding technology, and better disclosure that could broaden an institutional base currently below 2%.

Our verdict is constructive but cyclical. The key monitorables are H2 FY2027 margin recovery, order-intake commentary in the next CARE review, and early evidence that the company can move beyond its long-standing revenue ceiling.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / key datesBackground

Ajay Naishad Desai

Executive Director and Whole-time Director (promoter)

ED since at least 2011; signs results declarations; current term runs to 28 Feb 2027; re-appointment for five years from 1 Mar 2027 approved by the Board (6 Aug 2026) and shareholders (AGM 31 Jul 2026)

Public spokesman on automation (Rockwell case study) and on the IISc licence.

Ajay Nalin Parikh (DIN 00453711)

Executive Director and Whole-time Director (promoter)

With Axtel since 1992; re-appointed 1 Aug 2013, 1 Aug 2018 and 1 Aug 2023 (five-year term); continuation to 31 Jul 2028 approved at AGM 2026

First-class Bachelor of Engineering. Earlier career linked to the National Dairy Development Board ecosystem per AR 2013. Credited with developing a large range of equipment and setting up manufacturing.

Rajendra K. Bhavsar

Chief Financial Officer

Tenure not disclosed

—

Dharaben Mehulkumar Thakar

Company Secretary and Compliance Officer

From 2 Jun 2025

Replaced CS Prerna Sudeep Bokil (resigned effective 31 May 2025)

Board of Directors

DirectorCategoryNotes

Sandeep Lalwani

Chairman, Independent Director

On the board since at least 2012

Ajay Naishad Desai

Executive / Whole-time Director (promoter)

See above

Ajay Nalin Parikh

Executive / Whole-time Director (promoter)

See above

Ameet Nalin Parikh

Non-Executive Director (promoter group; related to Ajay Parikh)

Director since at least 2012

Ajit (Ajitsingh Mohansingh) Bubber (DIN 00454111)

Non-Executive Director

Retired by rotation and re-appointed at the AGMs of 10 Jul 2023 and 19 Aug 2025

Deepti Sharma

Independent Director

—

Nimish Patel

Independent Director

—

Paresh Jaisinh Rajda

Independent Non-Executive Director (per Blinkx)

Current status not confirmed in primary filings

Board & Management Changes

DateChange

13 May 2025

CS Prerna Bokil resigns (effective 31 May 2025); CS Dharaben Thakar appointed (effective 2 Jun 2025)

19 Aug 2025

Ajit Singh Bubber re-appointed on rotation

31 Jul 2026

AGM approves Ajay Desai's re-appointment and Ajay Parikh's continuation as WTDs, plus revised remuneration from 1 Aug 2026

6 Aug 2026

Board disclosure: Desai re-appointed from 1 Mar 2027; Parikh to continue until 31 Jul 2028

Shareholding Trend

Holder categorySep 2023Mar 2024Mar 2025Mar 2026Jun 2026

Promoters (%)

49.9549.9549.9549.9549.95

FIIs (%)

0.000.020.620.410.41

DIIs (%)

0.000.250.991.421.48

Public (%)

50.0649.7948.4548.2348.17

Number of shareholders

17,69819,74919,49318,62518,789

Major Shareholders

HolderStakeNote

Promoter group (Parikh, Desai and associated families)

49.95% combined

—

Solidarity Advisors Pvt. Ltd. and PACs

5.20%

Rose from 4.76% (768,951 shares) via open-market purchase on 19 Jun 2026

Aanchal N. Mehta

Not disclosed (below 5% after sale)

—

Domestic institutions (mutual funds etc.)

1.48%—

Foreign portfolio investors

0.41%—

Competitive Landscape

Key Competitors

CompetitorHome countryOverlap with AxtelRelative scalePositioning vs Axtel

Bühler AG

Switzerland

Grinding/milling, spice processing, chocolate and confectionery, extrusion

Multi-billion-dollar global leader

Technology and brand leader; much higher price point

GEA Group

Germany

Food process systems, dairy, powder handling, extrusion

Multi-billion-euro

Broad portfolio; competes on large greenfield projects

Hosokawa Micron Group

Japan

Size reduction, classification, powder processing

Large global

Fine/ultra-fine grinding leader; relevant to the cryogenic adjacency

Royal Duyvis Wiener

Netherlands

Cocoa and chocolate processing

Mid-size global

Chocolate-line competitor

Aasted / Sollich

Denmark / Germany

Chocolate moulding, enrobing, tempering, cooling tunnels

Mid-size global

Premium chocolate-equipment specialists

Napasol AG

Switzerland

Spice and herb steam sterilisation

Niche

Direct competitor in spice sterilisation

Russell Finex

UK

Sieves, separators, filters

Mid-size

Competes in sieving equipment

Clextral

France

Twin-screw extrusion

Mid-size

Extrusion competitor (Axtel works with Wenger)

Kilburn Engineering Ltd

India (listed)

Industrial dryers, food and chemical drying systems

—

Overlaps in dryers and dehydration

HLE Glascoat Ltd

India (listed)

Process equipment, filtration and drying for pharma and chemicals

—

Overlaps in pharma and chemical equipment

Mazda Ltd

India (listed)

Vacuum systems, evaporators, process equipment

—

Overlaps in evaporators and heat exchangers

Unorganised and regional Indian fabricators (Gujarat, Maharashtra)

India

Standard conveyors, mixers, sifters

Fragmented

Compete on price for standalone equipment

Competitor Detail

MetricAxtel FY2026

Revenue (INR Cr)

223.8

Revenue growth (%)

25.3

EBITDA margin (%)

18

Net margin (%)

13.9

Recent Developments

The company does not announce individual orders.

Company Snapshot

$25.8M

Revenue

228

Employees

1991

Founded

Panchmahal, India

Headquarters

SWOT Analysis

Strengths

  • Debt-free, cash-rich balance sheet. Zero borrowings at 31 Mar 2025 and 30 Sep 2025; free liquidity of ₹99 crore at 30 Sep 2025 (CARE).
  • High returns on capital. ROCE of 41% in FY2024 and 30% in FY2026; 5-year average ROE of about 20% (Screener).
  • Strong cash generation. FY2026 CFO of ₹71 crore was 197% of EBITDA; cumulative FY2022–26 FCF was about ₹127 crore.
  • Reputed, diversified clientele. More than 150 food-processing customers, mostly large organised FMCG (CARE, Feb 2026).
  • Order visibility. Order book of about ₹250 crore at 30 Sep 2025, roughly 1.1x TTM revenue (CARE).
  • Technology alliances. Wenger (USA), AnuTec (Switzerland), Rockwell Gold OEM, EHEDG membership, and the exclusive IISc licence (Sept 2026).
  • Improving credit profile. Upgraded from CARE BBB+/A2 (2023–24) to A-/A2+ (Feb 2025), reaffirmed Feb 2026.

Weaknesses

  • Moderate scale. FY2026 TOI of about ₹224 crore, well below CARE's ₹350 crore upgrade trigger.
  • Earnings volatility. PAT went from ₹32.1 crore (FY2024) to ₹18.0 crore (FY2025) to ₹31.2 crore (FY2026). Quarterly OPM ranged from 5.6% to 23.9% over 13 quarters.
  • Weak 5-year growth. Screener's 5-year sales CAGR is 8% and profit CAGR is 4%.
  • Single plant and single segment. All manufacturing is at Halol (CARE).
  • Fixed-price contracts and limited pricing power with large FMCG buyers (CARE).
  • Thin disclosure. No investor presentations, earnings calls, segment detail or guidance were found, which hampers institutional coverage. FII plus DII holding is only about 1.9%.
  • Key-person concentration. Two promoter WTDs, both with the company since the early 1990s.

Opportunities

  • Cryogenic grinding adjacency in polymer, rubber and resin powders currently imported, with exclusive IISc rights (Sept 2026).
  • Recovery in Indian FMCG capex. FY2026 Q2–Q4 revenue growth ran at 21–88% YoY.
  • Automation retrofits for compliance and traceability, building on Rockwell case studies.
  • Export growth to emerging markets, as highlighted in the company MD&A.
  • R&D and test centre to win development-stage projects (website).
  • Balance sheet capacity for acquisitions or capacity expansion; ₹81 crore of investments is currently idle in treasury.

Threats

  • Capex-cycle downturns. FY2025 revenue fell 20% when end-user capex slowed (CARE).
  • Raw-material inflation (stainless steel) on long-tenor fixed-price contracts (CARE).
  • Competition from global OEMs (Bühler, GEA) moving down-market or localising in India (analyst view).
  • Global economic uncertainty hitting export demand and realisations (company MD&A risk list).
  • Working-capital reversal. FY2026 cash benefited from payables rising to 125 days; normalisation could cut CFO.
  • Execution risk on new technology. The cryogenic system is prototype-stage and its commercial success is unproven.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
17 Apr 2025Reg. 74(5) depository compliance certificate for Q4 FY2025Routine
6 May 2025Board meeting intimation for FY2025 resultsRoutine
13 May 2025FY2025 audited results: PAT ₹18.03 crore (−44%), revenue ₹178.6 crore (−20%); unmodified audit opinionCyclical downturn confirmed
13 May 2025Sharp & Tannan appointed internal auditor for FY2026; CS change approvedGovernance
31 May / 2 Jun 2025CS Prerna Bokil exits; CS Dharaben Thakar joinsKMP change
Late May 2025Annual Secretarial Compliance Report (Reg. 24A) filedRoutine compliance
Jun–Jul 2025Trading window closure ahead of Q1Routine
16–17 Jul 2025Q1 FY2026: sales ₹27.22 crore (−39.1%), PAT ₹1.90 crore (−53.8%); stock falls 4.6% to ₹468.50Weakest quarter in recent history
16 Jul 2025Board recommends a final dividend of ₹6 per share for FY2025FY2025 payout reaches about 99%
12 Aug 2025Ex-date for the FY2025 final dividendShareholder return
19 Aug 202533rd AGM; resolutions passed; Ajit Bubber re-appointedGovernance
4 Nov 2025Board meeting intimation for 11 Nov 2025 (H1 results)Routine
11 Nov 2025Q2 FY2026: sales ₹67.34 crore (+20.6% YoY), PAT ₹10.12 crore (+71.5%)Recovery begins
14–29 Nov 2025Several insider-trading disclosures, including a sale by Meena Pathak (1,207 shares)Minor insider activity
–Q3 FY2026: sales ₹58.63 crore (+45% YoY), PAT ₹7.98 crore (+145%)Recovery accelerates
30 Jan 2026Reg. 30 disclosure on credit-rating review—
5 Feb 2026CARE reaffirms A-; Stable / A2+ on ₹50 crore of facilities; order book of about ₹250 crore citedCredit strength confirmed
2 Mar 2026Interim dividend of ₹12 per share (120%); record date 9 Mar 2026; payment by 25 Mar 2026Highest dividend ever
26 Mar 2026Trading window closureRoutine
18 Apr 2026Q4 FY2026 shareholding pattern: promoters 49.95%Stable control
7 May 2026FY2026 audited results: revenue ₹223.77 crore (+25.3%), PAT ₹31.16 crore (+72.8%), EPS ₹19.29; Q4 sales ₹70.57 crore; final dividend of ₹12 recommended (confirming the interim)Return to near-record earnings
28 May 2026Annual Secretarial Compliance Report filedRoutine
19–22 Jun 2026Solidarity Advisors raises stake to 5.20% (SAST Reg. 29(1))Institutional endorsement
25 Jun 2026Trading window closureRoutine
9 Jul 2026FY2026 (34th) Annual Report filed; AGM notice for 31 Jul 2026 with revised WTD remuneration from 1 Aug 2026Governance
31 Jul 202634th AGM (video conference) approves accounts, dividend, and WTD re-appointment and continuationLeadership continuity to 2028–2032
6 Aug 2026Q1 FY2027: sales ₹32.31 crore (+18.7%), PAT ₹1.96 crore (+3.2%), OPM 7.83%; stock falls about 8.2% to ₹432Seasonal weakness; margin concern
6 Aug 2026Board approves Ajay Desai's re-appointment (from 1 Mar 2027) and Ajay Parikh's continuation (to 31 Jul 2028)Succession stability
7–8 Sep 2026Exclusive technology licence with FSID-IISc for cryogenic grindingNew adjacency
28 Sep 2026Trading window closure ahead of Q2 FY2027 resultsQ2 results due around Nov 2026
15 Oct 2026Reg. 74(5) certificate for the quarter ended 30 Sep 2026Routine

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 1,440 Mn in FY2022 to INR 2,238 Mn in FY2026.
Axtel Industries Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations1,4401,8012,2331,7862,238
Gross profit6878481,1609051,291

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Screener.in, Axtel Industries Ltd: P&L, quarterly results, balance sheet, cash flow, ratios, shareholding, announcements (accessed 20 Oct 2026). (screener.in)
  2. CARE Ratings, Press Release: Axtel Industries Limited, 5 February 2026. (careratings.com)
  3. StockAnalysis.com, Axtel Industries income statement (BOM:523850) and company profile (NSE:AXTEL). · stockanalysis.com
  4. Axtel Industries corporate website, Our Company. (axtelindia.com)
  5. Rockwell Automation case study: Axtel Gains Precision in Chocolate Molding and Spice Blending. (rockwellautomation.com)
  6. FilingReader: Axtel Industries profit jumps 73% (7 May 2026); Axtel secures IISc tech agreement (7 Sep 2026). · filingreader.com
  7. Equitybulls: Axtel Industries and FSID, IISc enter Technology Licensing Agreement (8 Sep 2026). (equitybulls.com)
  8. JM Financial / Capital Market: Axtel Industries net profit rises 3.16% in June 2026 quarter (6 Aug 2026). (jmfinancialservices.in)
  9. Business Standard / Capital Market: Axtel Industries slumps after weak Q1 performance (17 Jul 2025). (business-standard.com)
  10. ScanX: Solidarity Advisors raises stake to 5.20%; FY26 results; AGM 2026; WTD re-appointment. · scanx.trade
  11. IIFL (indiainfoline.com): company summary, Directors' Report, MD&A, Auditors' Report. (indiainfoline.com)
  12. Value Research Online: stock page and dividend announcements. (valueresearchonline.com)
  13. Vogue/BFSL and Emkay (Dion Global): dividend history and company information. (voguestock.in)
  14. BSE historical annual reports 2012, 2013, 2014, 2016 and BSE filing on Ajay Parikh's re-appointment (2023). (bseindia.com)
  15. MarketsMojo, Blinkx, Upstox, ICICIdirect, Kotak Securities, Anand Rathi, Nirmal Bang, Torus Digital, Sharekhan, Sharpely, Trendlyne: management lists, price history, NSE status, insider disclosures.
  16. EMIS company profile (employee count, 2025). (emis.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.